🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity In this review in ESMO Open we address this topic👇🏻 OncoAlert sciencedirect.com/science/articl…

Presented at #AACR25: Among patients with tumors harboring tyrosine kinase domain mutations who received zongertinib (a selective inhibitor of the HER2 tyrosine kinase), 71% had a response, and median progression-free survival was 12.4 months. Full study results:

Opportunities for Artificial Intelligence in #Oncology: From the Lens of Clinicians and Patients. ascopubs.org/doi/10.1200/OP… ASCO Journal of Clinical Oncology JCO Oncology Practice #ArtificialIntelligence #CancerResearch #CancerCare #MedTech #DigitalHealth #AI

Multicenter analysis of high-dose chemotherapy regimens for the treatment of pts with refractory or recurrent GCTs in ESMO Open. 111 pts retrospectively analysed, similar results with CE vs TICE, potential benefit with TICE in higher risk disease. esmoopen.com/action/showPdf…

Proud to share our review in Cancer Treatment Reviews: We explore how trial designs are evolving to prioritize safety, biomarkers & patient-centered care. Thanks to Prof. G Curigliano MD PhD and Dario Trapani #Oncology #DoseOptimization #CancerTrials OncoAlert

Which role for ADCs in CNS malignancies? Have a look! EANO SNO OncoAlert OncoDaily mdpi.com/2072-6694/17/9…

📣New advance in neuro-oncology! OncoAlert PET RANO BM 1.0 criteria standardize #brainmetastases assessment using amino acid PET, enhancing clinical trials & patient care. Read more: 📖 Nature Medicine #btsm nature.com/articles/s4159…

New #JITC article: Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study bit.ly/4dpztXb John Connolly

Loss of CDKN2A/B and morphological grade 4 criteria together in IDHm grade 4 Astro worse than if you have only one of them link.springer.com/article/10.100…

This work is making the rounds; the idea being that some survival curves stay just above the median - “skimming the median” - and looking at just median survival can be misleading jamanetwork.com/journals/jamao…

🚨Excited to represent the International Society of Liquid Biopsy at #ASCO25! Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities! Got questions about the society? We’ve got answers. Come to connect!🩸 ASCO Christian Rolfo Umberto Malapelle David Gandara Carolina Reduzzi

Final Update CATNON ASCO 2025 · Median F/U 11 yrs · NO sig benefit concurrent TMZ · Sig benefit (HR 0.54) Adjuvant TMZ in IDHm (median OS 12.5 years) · NO benefit w/TMZ for IDHwt

A lot of exciting data came out of #ASCO25—but some presentations were a sobering wake-up call. As Sonya Reid, MD MPH highlighted, nearly 50% of patients with mTNBC don’t receive any treatment beyond first-line therapy. This is unacceptable. In 2025, this should not be the reality.

How to select pts with HCC for various local therapies? RFA ,MWA , TACE , SIRT , SBRT . Useful for clinical decision-making. Taken from #asco25 ASCO Do u agree ? Yakup Ergün Dr. Nina Niu Sanford Jeff Ryckman OncoAlert Kate Sears

Quality-of-life results contribute to the definition of treatment value, inform communication and impact the choice among various treatment options. Massimo Di Maio provides a practical guide to interpretation of quality-of-life results. eviden.cc/431mUhd

❄️Winter of cancer immunotherapy is here. 𝐀𝐥𝐥-𝐜𝐨𝐦𝐞𝐫𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 & 𝐍𝐞𝐭𝐰𝐨𝐫𝐤-𝐞𝐟𝐟𝐞𝐜𝐭 slowed progress-we’ve hit a plateau. Time to prioritize innovation over convention! Editorial out in JTO & JTO CRR bit.ly/4eEVcv4 Fabio Salomone Antonio Nuccio

What is the impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections? ✅ Just Accepted ✍️ linda bussini Humanitas University Humanitas Milano 🔗 academic.oup.com/cid/advance-ar…

Common Terminology Criteria for Adverse Events (CTCAE) has 26 categories for 837 terms, and 3,185 options when you account for Grade 1 to 5 🤯! I wanted to be able to interactively visualize CTCAE so I some wrote code 🧑‍💻 TheCodingDocs.com Take a look at --> thecodingdocs.com/clincal/ctcae